Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. (Q46630536)
Jump to navigation
Jump to search
scientific article published on 5 July 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. |
scientific article published on 5 July 2017 |
Statements
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors (English)
Jeffrey R Infante
Roger B Cohen
Kevin B Kim
Howard A Burris
Gregory Curt
Ugochi Emeribe
Delyth Clemett
Helen K Tomkinson
Patricia M LoRusso
1 October 2017
1 reference